Mechanisms of Atheroprotection by Fenofibric Acid (ABT 335) Added to a Statin in Subjects With Insulin Resistance (Hypertriglyceridemia and Low HDL-C).

Trial Profile

Mechanisms of Atheroprotection by Fenofibric Acid (ABT 335) Added to a Statin in Subjects With Insulin Resistance (Hypertriglyceridemia and Low HDL-C).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Choline fenofibrate (Primary)
  • Indications Hypertriglyceridaemia; Low HDL cholesterol
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Planned end date changed from 1 Nov 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Additional trial identifier 00030151 identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top